Patents Assigned to Merck Sharp & Dohme
  • Drug Delivery System for the Delivery of Antiviral Agents
    Publication number: 20190388336
    Abstract: This invention relates to novel implant drug delivery systems for long-acting delivery of antiviral drugs. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: June 15, 2017
    Publication date: December 26, 2019
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Stephanie Elizabeth Barrett, Marian E. Gindy, Li Li, Seth P. Forster, Ryan S. Teller
  • 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
    Patent number: 10512638
    Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine 5 receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: December 24, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael T. Rudd, David M. Tellers, Jenny Miu-Chun Wai
  • Inhibitors of the renal outer medullary potassium channel
    Patent number: 10513518
    Abstract: The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: December 24, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Reynalda K. deJesus, Qinghong Fu, Jinlong Jiang, Haifeng Tang
  • METHOD OF MICROWAVE VACUUM DRYING SPHERICAL-SHAPED PELLETS OF BIOLOGICAL MATERIALS
    Publication number: 20190383556
    Abstract: Methods for preparing dried pellets of biological materials are described. The pellets can have a substantially spherical shape and are prepared by freezing droplets of a liquid composition of a desired biological material on a solid surface followed by microwave vacuum drying the frozen droplets. These methods are useful for preparing dried pellets having a high concentration of a desired biological material, in particular a therapeutic protein or vaccine, and which have a faster reconstitution time than lyophilized powder cakes prepared in vials.
    Type: Application
    Filed: August 30, 2019
    Publication date: December 19, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Akhilesh Bhambhani, Robert K. Evans, Jessica Sinacola, Rebecca Lizzano
  • ARYL SULFONAMIDES AS BLT1 ANTAGONISTS
    Publication number: 20190382363
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.
    Type: Application
    Filed: November 28, 2016
    Publication date: December 19, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, Jongwon Lim, Satyanarayana Tummanapalli, Phieng Siliphaivanh, Kerrie Spencer
  • Tricyclic compounds as inhibitors of mutant IDH enzymes
    Patent number: 10508108
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)? or —N?; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christian Fischer, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, J. Michael Ellis, Sara Esposite, Dawn M. Hoffman, Chunhui Huang, Solomon D. Kattar, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Dann L. Parker, Jr., Michael H. Reutershan, Nunzio Sciammetta, Pengcheng P. Shao, David L. Sloman, Wanying Sun, Feroze Ujjainwalla, Zhicai Wu, Yang Yu, Craig R. Gibeau
  • Liposomal Formulations for Allosteric AKT Inhibitors
    Publication number: 20190374468
    Abstract: Disclosed herein is a lipid nanoparticle (LNP) composition comprising (a) an Akt inhibitor; (b) DSPC; (c) cholesterol; and (d) PEG-DMG. Also disclosed herein is a method for preparing the lipid composition using a scalable tangential flow micro-mixing technology.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 12, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael Hughes Smith, Marian Gindy
  • PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE
    Publication number: 20190375716
    Abstract: In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-? receptor (LXR?) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
    Type: Application
    Filed: October 9, 2017
    Publication date: December 12, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael T. Rudd, Zhaoyang Meng, Jenny Wai, David Jonathan Bennett, Edward J. Brnardic, Nigel J. Liverton, Shawn J. Stachel, Yongxin Han, Paul Tempest, Jiuxiang Zhu, Xuewang Xu, Bin Zhu, Chuanman Huang
  • Substituted Heterocyclic Compounds as Inhibitors of PRDM9
    Publication number: 20190374526
    Abstract: The present invention relates to Substituted Heterocyclic Compounds of Formula (I): R1—R2—R3—R4?? (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, and R4 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Heterocyclic Compound, and methods of using the Substituted Heterocyclic Compounds for inhibiting PRDM9 activity in a subject or for treating or preventing a disease mediated by PRDM9 activity.
    Type: Application
    Filed: June 6, 2019
    Publication date: December 12, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Christian Fischer, Solomon D. Kattar, John M. Sanders
  • SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
    Patent number: 10500186
    Abstract: The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). The present invention also relates to methods for preventing neuronal damage following the incidence of ischemic stroke and close-head traumatic brain injury in animals comprising the step of administering to an animal, in need of such treatment, a therapeutically effective amount of ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: December 10, 2019
    Assignees: Merck Sharp & Dohme Corp., Pfizer Inc.
    Inventors: Ramachandra G. Naik, Elizabeth S. Ommen, James Michael Rusnak, Steven G. Terra
  • CTLA4 binders
    Patent number: 10501542
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: December 10, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, Robert A. Kastelein
  • Substituted bicyclic fused ring compounds as indoleamine-2,3-dioxygenase inhibitors
    Patent number: 10501458
    Abstract: Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the general formula (I) detailed within.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: December 10, 2019
    Assignees: Iomet Pharma Ltd., Merck Sharp & Dohme Corp.
    Inventors: Phillip M. Cowley, Alan Wise, Thomas J. Brown, Meredeth A. McGowan, Hua Zhou, Yongxin Han
  • Prefilled disposable injection device
    Patent number: 10500338
    Abstract: A drug delivery device comprising a drug container extending between a distal end and a proximal end and is capable of being compressed into a single plane; a body extending between proximal and distal ends comprising a hollow space for containing the drug container; and a plunger extending between proximal and distal ends, wherein the distal end of the plunger engages telescopically with the proximal end of the body, wherein the plunger comprises at least one pair of protrusions, wherein the protrusion is capable of compressing the drug container as the plunger moves towards the proximal end of the drug delivery device, by applying a force to the drug container that is perpendicular to the movement of the plunger.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: December 10, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Annaniy Berenshteyn
  • SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS
    Publication number: 20190365727
    Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: January 23, 2018
    Publication date: December 5, 2019
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Tao Yu, John A. McCauley, Alan Whitehead, James M. Apgar, Izzat T. Raheem, Guizhen Dong, Sherman T. Waddell, Hong Li
  • ANTIDIABETIC HETEROCYCLIC COMPOUNDS
    Publication number: 20190367495
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Application
    Filed: December 1, 2017
    Publication date: December 5, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael Miller, Harry R. Chobanian, Shuwen He, Jinsong Hao, Barbara Pio
  • Co-agonists of the glucagon and GLP-1 receptors
    Patent number: 10493125
    Abstract: Co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: December 3, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Paul E. Carrington, Antonello Pessi, Armin Lahm, Elisabetta Bianchi, Anna Demartis
  • Factor XIIa Inhibitors
    Publication number: 20190352294
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.
    Type: Application
    Filed: November 13, 2017
    Publication date: November 21, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashwin U. Rao, Brian Alexander McKittrick, Matthew Lombardo, Jacqueline D. Hicks, Amy Bittner McCracken, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu, Ping Lan, John S. Debenham, Brent R. Whitehead, Jerry A. Taylor, Zhongxiang Sun, Revathi Reddy Katipally, Jonathan E. Gable, Markus K. Dahlgren, Sathesh P. Bhat
  • Tetracyclic heterocycle compounds useful as HIV integrase inhibitors
    Patent number: 10479801
    Abstract: The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, R1, R2, R3 and R7 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: November 19, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thomas H. Graham, Tao Yu, Yonglian Zhang, John A. McCauley
  • Pegylated interleukin-10
    Patent number: 10471126
    Abstract: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: November 12, 2019
    Assignee: Merck Sharp & Dohme Ltd
    Inventors: Seoju Lee, David C. Wylie, Susan V. Cannon-Carlson
  • Autoinjector pen
    Patent number: D870270
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: December 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Greg Burkett, Shu Kuen Chang, Angie Kim, Jin Ko, Scott Mackie, Philip G. Green, Sharad Gupta, Angela M. Amend Kwasnik, Christin L. O'Neill, Robert Stianchi, Witold Swiatek